Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joins Steve Darling from Proactive Vancouver to provide an update that a protocol is planned for a physician initiated phase 2 clinical study of NP-120 for COVID-19 infected patients in South Korea. Moreau telling Proactive how they are fast-tracked for this trial and what the next steps will be.
0 Comments